Anti-parkinson medications

00:00 / 00:00


Anti-parkinson medications


0 / 16 complete


Anti-parkinson medications

of complete

External References

First Aid








Amantadine p. 198, 568


amantadine toxicity p. 568


Anti-parkinson medications are used to treat Parkinson’s disease, which is a movement disorder where the dopamine-producing neurons in the substantia nigra of the brain undergo degeneration. It’s a progressive, adult-onset disease, and is more common with age, affecting about 1% of people over 60. The substantia nigra is a part of the basal ganglia, a collection of nuclei in the brain that control movement through their connections with the motor cortex. The substantia nigra actually can be split into two sub-regions. First, there’s the pars reticulata, which receives signals from another part of the basal ganglia called the striatum, and relays messages to the thalamus via neurons rich in the neurotransmitter GABA, also known as gamma-aminobutyric acid. Second, there’s the pars compacta, and this is the part of the substantia nigra affected in Parkinson’s.

The pars compacta sends messages to the striatum via neurons rich in the neurotransmitter dopamine, forming the nigrostriatal pathway, which helps to stimulate the cerebral cortex and initiate movement. In Parkinson’s disease, the neurons in the substantia die, so the individual may experience hypokinesia, which is difficulty initiating movements, and bradykinesia, or slowed movements. The substantia nigra also helps to calibrate and fine tune a person’s movements, which leads to the other clinical features of Parkinson’s, like “pill-rolling” tremor, which is the repetitive, involuntary rubbing of the thumb and index finger, as well as rigidity, stooped posture, and an expressionless, mask-like face. As the neurodegeneration progresses, non-motor dysfunction can appear, including depression, dementia, sleep disturbances, and difficulty smelling.


Parkinson's disease is a neurodegenerative disorder in which there is progressive depletion of dopaminergic neurons in the basal ganglia, especially in the substantia nigra. Anti-Parkinson medications are drugs used in the management of this disorder.

There are a few different classes of medications used to manage Parkinson's Disease. These include dopamine precursors such as levodopa (L-Dopa); dopaminergic drugs such as bromocriptine that increases the amount of dopamine in the brain; monoamine oxidase (MAO)-B inhibitors like rasagiline that blocks an enzyme that breaks down dopamine; and catechol-O-methyltransferase (COMT) inhibitors such as tolcapone which work by stopping an enzyme from breaking down levodopa.


  1. "Katzung & Trevor's Pharmacology Examination and Board Review,12th Edition" McGraw-Hill Education / Medical (2018)
  2. "Rang and Dale's Pharmacology" Elsevier (2019)
  3. "Goodman and Gilman's The Pharmacological Basis of Therapeutics, 13th Edition" McGraw-Hill Education / Medical (2017)
  4. "The history of dopamine and levodopa in the treatment of Parkinson's disease" Movement Disorders (2008)
  5. "Drugs for Parkinson's disease" Treat Guidel Med Lett (2013)
  6. "The role of extended-release amantadine for the treatment of dyskinesia in Parkinson's disease patients" Neurodegener Dis Manag (2018)

Copyright © 2023 Elsevier, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

Cookies are used by this site.

USMLE® is a joint program of the Federation of State Medical Boards (FSMB) and the National Board of Medical Examiners (NBME). COMLEX-USA® is a registered trademark of The National Board of Osteopathic Medical Examiners, Inc. NCLEX-RN® is a registered trademark of the National Council of State Boards of Nursing, Inc. Test names and other trademarks are the property of the respective trademark holders. None of the trademark holders are endorsed by nor affiliated with Osmosis or this website.